Oxaliplatin (Eloxatin)
Chemotherapy · Approved since 2002
Description
Oxaliplatin is a third-generation platinum-based chemotherapy agent that forms a cornerstone of colorectal cancer treatment in both adjuvant and metastatic settings. It is administered as part of combination regimens such as FOLFOX (with 5-fluorouracil and leucovorin) and CAPOX/XELOX (with capecitabine) for treating stage III colon cancer following surgical resection and metastatic colorectal cancer regardless of molecular subtype. The drug is effective across different CRC molecular profiles including KRAS-mutated, BRAF wild-type, and microsatellite stable (MSS) tumors, making it a versatile backbone therapy. Oxaliplatin-based regimens are frequently combined with targeted agents like bevacizumab or immunotherapy agents in specific patient populations.
Mechanism of Action
Oxaliplatin functions as a DNA alkylating agent that forms platinum-DNA adducts by cross-linking DNA strands, primarily creating intrastrand crosslinks between adjacent guanine and adenine bases. These DNA lesions block DNA replication and transcription, triggering apoptosis in rapidly dividing cancer cells. Unlike other platinum compounds, oxaliplatin's diaminocyclohexane carrier ligand provides enhanced activity against colorectal cancer cells and helps overcome some forms of platinum resistance.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Eloxatin |
| Category | Chemotherapy |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS approved in CRC |
| Administration | IV |
| Year Approved | 2002 |
| Clinical Trials | 846 |
Regimens with this Drug
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.